Key result
Statin use in hypertensive patients was associated with significantly poorer glycaemic control, reflected by higher HbA1c levels (adjusted OR 1.290) compared to non-users.
Why the study?
Does statin therapy worsen glycaemic control in hypertensive patients?
Cohort (n=1,060)
No
Does statin therapy worsen glycaemic control in hypertensive patients?
Odds Ratio: 1.29 (95% CI 1.006–1.654)
Absolute Event Rate: 7.5% vs 6.9%
p-value: p=0.044
Statin use is associated with poorer glycaemic control in hypertensive patients, reinforcing the need for regular HbA1c monitoring in this population.
BACKGROUND: The US Federal and Drug Administration (FDA) recently revised statin drug labels to include the information that increases in fasting serum glucose and glycated haemoglobin levels have been reported with the use of statins. Yet in a survey, 87% of the doctors stated that they had never or infrequently observed increases in glucose or HbA1c levels in patients on statin. In this study we would like to determine the association between the use of statins and glycaemic control in a retrospective cohort of patients with hypertension. METHODS: A retrospective review of 1060 medical records of patients with hypertension at a primary care clinic was conducted. These records were selected using systematic random sampling (1:4). Data on patient socio-demographic factors; clinical profile; investigation results and prescribed medications were collected. Independent t-test was used for continuous variables while Pearson's χ2 test was used for categorical variables. Logistic regression was done to adjust for confounders. RESULTS: 810 (76.4%) patients with hypertension were on statins, out of which 792 (97.8%) were taking simvastatin 10 mg or 20 mg daily. Analysis of the whole group regardless of diabetes status showed that the statin user group had higher HbA1c and fasting blood glucose values. The difference in HbA1c levels remained significant (adjusted OR = 1.290, p = 0.044, 95% CI 1.006, 1.654) after adjustment for diabetes, diabetic medication and fasting blood glucose. In the study population who had diabetes, statin users again had significantly higher HbA1c level compared to statin non-users. This difference remained significant (adjusted OR 1.208, p = 0.037, 95% CI 1.012, 1.441) after adjustment for age and diabetic medications. CONCLUSIONS: Statins use is associated with increased HbA1c levels among hypertensive patients and hypertensive patients with diabetes. Clinicians managing hypertensive patients on statins should consider monitoring the HbA1c level and ensure that those with diabetes have their hyperglycaemia kept under control.
No takes yet. Share an insight, caveat, or question.
Liew et al. (2014) conducted a cohort in Hypertension (n=1,060). Statin use vs. Statin non-users was evaluated on HbA1c levels (OR 1.290, 95% CI 1.006-1.654, p=0.044). Statin use in hypertensive patients was associated with significantly poorer glycaemic control, reflected by higher HbA1c levels (adjusted OR 1.290) compared to non-users.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: